ArticleJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2026
Real-world effectiveness and tolerability of wake-promoting agents for residual sleepiness in treated obstructive sleep apnea.
Article in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Residual sleepiness despite effective positive airway pressure (PAP) therapy remains a persistent clinical problem in obstructive sleep apnea (OSA). This retrospective study evaluated real-world use, effectiveness, and tolerability of modafinil, armodafinil, and solriamfetol in 50 adults with OSA and residual sleepiness. Most patients received modafinil (80%) as their initial agent. Complete, partial, and poor responses occurred in 26%, 44%, and 30% of patients, respectively. Adverse events were reported in 38%-predominantly neurologic and psychiatric-and led to discontinuation in ten cases. Response did not correlate with apnea severity, body mass index, or PAP adherence, and no single agent demonstrated superior benefit. These findings contrast with the stronger efficacy and tolerability reported in randomized controlled trials, underscoring the need for individualized therapy and realistic counseling about benefits and side effects when prescribing wake-promoting agents in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.